Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Merieux Developpement
AddedFeb 13, 2024
UpdatedJun 28, 2026
Merieux Developpement

Merieux Developpement

Operating

Mérieux Développement, a growth and venture capital firm, specializes in healthcare and nutrition sectors, supporting innovative companies globally.

Location
Lyon, Rhône, FR
Founded
2009
Firm
Compare
Portfolio
Employees

Mérieux Développement is specialized in Growth and Venture capital transactions in the healthcare and nutrition sectors. We support companies with products or services offering true differentiation and capacity to create substantial value over the long term.

Our investment team, based in Europe and North America, brings its expertise and international network to help entrepreneurs disrupt and grasp substantial market opportunities. Mérieux Développement is an affiliate of Institut Mérieux, which employs approximately 17,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2017.

Merieux Developpement - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments14
Current Portfolio Count7
Total Portfolio Exits0

Top Investment Stages

Series C7 (50.0%)
Series B3 (21.4%)
Series D2 (14.3%)
Private Equity1 (7.1%)
Series Unknown1 (7.1%)

Stage Mix

Series C 50%Series B 21%Series D 14%Private Equity 7%Series Unknown 7%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Amphivena Therapeutics logo

Amphivena Therapeutics

Inscripta logo

Inscripta

Xeris Biopharma Holdings logo

Xeris Biopharma Holdings

Novacap logo

Novacap

Twist Bioscience logo

Twist Bioscience

Origene Technologies logo

Origene Technologies

Imaginab logo

Imaginab

Proclara Biosciences logo

Proclara Biosciences

Merieux Developpement - Similar Investment Firms

M Capital Partners logo

M Capital Partners

M Ventures logo

M Ventures

BNP Paribas Développement logo

BNP Paribas Développement

bnpparibas.com

PLS Venture Capital Partners logo

PLS Venture Capital Partners

Merus Capital logo

Merus Capital

meruscap.com

Merlin Ventures logo

Merlin Ventures

merlin.vc

Inbio Ventures logo

Inbio Ventures

Crédit Mutuel Innovation logo

Crédit Mutuel Innovation

Merck Capital Ventures logo

Merck Capital Ventures

merck.com

Meridian Venture Partners logo

Meridian Venture Partners

Merlin Nexus logo

Merlin Nexus

Merisis Venture Partners logo

Merisis Venture Partners

Montreux Equity Partners logo

Montreux Equity Partners

mepvc.com

Medingenii Capital logo

Medingenii Capital

medingenii.com

Amicus Capital Partners logo

Amicus Capital Partners

Merieux Developpement - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end